Biogen's Aduhelm Defense Highlights Therapeutic Area Discrepancies

 
• By Jessica Merrill
  
change of direction
Biogen hopes CMS will change its decision on Aduhelm coverage • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Medicare

More from Government Payers